Novartis has named its new Chief Financial Officer, Mehta, as part of management updates. The Swiss pharma company slightly raised its full-year sales guidance despite reporting Q2 sales figures that slightly missed analyst expectations. Additionally, Novartis initiated a $10 billion share buyback program. These moves reflect ongoing strategic leadership and financial adjustments as the company navigates market conditions in 2025.